☆ 4.5 Review

Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights

JOURNAL OF HEPATOCELLULAR CARCINOMA (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States

Nabihah Tayob et al.

Summary: In this study, researchers monitored hepatocellular carcinoma and tested the efficacy of several biomarkers. They found that GALAD had a higher sensitivity for detecting early HCC, but also showed false positive results. Its performance was comparable to AFP-L3 and HES.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Add to Collection

Article Gastroenterology & Hepatology

GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis

Amit G. Singal et al.

Summary: Evaluation of the biomarker GALAD for early detection of HCC in a cohort of patients with cirrhosis demonstrates high sensitivity.

HEPATOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Final results of adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis

Masatoshi Kudo et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Thomas Yau et al.

Summary: First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma, but clinical activity and a favorable safety profile were observed in some patients.

LANCET ONCOLOGY (2022)

Add to Collection

Review Gastroenterology & Hepatology

Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma

Hira Hanif et al.

Summary: Alpha-fetoprotein (AFP) is a tumor marker for hepatocellular carcinoma (HCC), but its utility is limited. However, combining AFP with other novel biomarkers can improve its accuracy. Additionally, increased AFP levels may be associated with liver diseases and other non-hepatic disorders.

WORLD JOURNAL OF GASTROENTEROLOGY (2022)

Add to Collection

Article Genetics & Heredity

Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial

Jung Yong Hong et al.

Summary: This study comprehensively characterized the genomic properties of hepatocellular carcinoma (HCC) patients in response to pembrolizumab treatment. It identified that the infiltration of cytotoxic T cells, increased active circulating CD8+ T cells, and down-regulation of neutrophil-associated markers significantly contributed to the effectiveness of pembrolizumab therapy. Female gender, PD-L1 positivity, and low neutrophil-to-lymphocyte ratio (NLR) were also identified as contributing factors to pembrolizumab response.

GENOME MEDICINE (2022)

Add to Collection

Article Gastroenterology & Hepatology

Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma

Naga P. Chalasani et al.

Summary: The study found that multitarget HCC blood test may significantly improve early stage HCC detection, providing more treatment opportunities for patients and reducing mortality.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Article Oncology

Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials

Josep M. Llovet et al.

Summary: Ramucirumab provides a survival benefit for patients with high AFP levels in aHCC. Geographical region, ECOG score, AFP level, Child-Pugh score, extrahepatic spread, neutrophil-to-lymphocyte ratio, alkaline phosphatase, and aspartate aminotransferase are independent prognostic factors associated with poor outcome. High drug exposure and treatment-related hypertension are associated with increased benefit from Ramucirumab.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab plus Bevacizumab Treatment of Hepatocellular Carcinoma

Andrew X. Zhu et al.

Summary: This study investigated the potential of on-treatment alpha-fetoprotein (AFP) response as a surrogate biomarker for prognosis in hepatocellular carcinoma patients receiving atezolizumab + bevacizumab. The results showed that AFP cutoffs of >= 75% decrease and <= 10% increase from baseline at 6 weeks could distinguish responders and patients with disease control. These AFP cutoffs were associated with longer overall survival and progression-free survival in patients, particularly those with hepatitis B virus etiology.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study

Gui-Qi Zhu et al.

Summary: In this study, the value of ctDNA in predicting early tumor recurrence and monitoring tumor burden in HCC patients was investigated. The presence of certain gene mutations in ctDNA, such as NRAS, NEF2L2, and MET, was associated with shorter time to recurrence, showing high predictive performance. Additionally, the median VAF of mutations in preoperative ctDNA served as a strong independent predictor of RFS for individuals with HCC.

MOLECULAR ONCOLOGY (2022)

Add to Collection

Article Oncology

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial

Yongxiang Xia et al.

Summary: Perioperative camrelizumab plus apatinib shows promising efficacy and manageable toxicity in patients with resectable HCC. DCs infiltration might be a predictive marker of response to camrelizumab and apatinib as well as patients' recurrence. ctDNA as a compose biomarker can predict pathological response and relapse. Abnormal glucose metabolism in patients with multifocal HCC may be related to different sensitivity of treatment in different lesions.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study

Beom Kyung Kim et al.

Summary: In the first-line treatment of unresectable HCC, ATE/BEV and LENV had comparable clinical efficacy and safety, with no significant differences observed.

CANCERS (2022)

Add to Collection

Article Oncology

Application of circulating tumor DNA for prediction and surveillance of tumor recurrence after liver transplantation: A pilot study.

Ao Huang et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Circulating tumor DNA is a potential prognostic risk factor of recurrence in patients with hepatocellular carcinoma treated by liver transplantation.

Nan Jiang et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial

Robin Kate Kelley et al.

Summary: This study evaluated the combination of cabozantinib and atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma. The combination treatment group showed better progression-free survival compared to the sorafenib group, but overall survival did not reach statistical significance. Common adverse events in the combination group included liver enzyme elevation, hypertension, and skin reactions. The study suggests that cabozantinib plus atezolizumab may be a treatment option, but further research is needed.

LANCET ONCOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

Andrew X. Zhu et al.

Summary: This study analyzed tumor samples from patients with hepatocellular carcinoma and found that combination therapy with atezolizumab and bevacizumab was effective in treating this type of cancer. Patients with high expression of VEGF Receptor 2, regulatory T cells, and myeloid inflammation signatures showed better outcomes with the combination therapy compared to atezolizumab alone. These findings provide insights into baseline immune and genetic features that can identify patients who will benefit from the combination therapy of atezolizumab and bevacizumab in advanced hepatocellular carcinoma.

NATURE MEDICINE (2022)

Add to Collection

Article Oncology

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

M. Rimini et al.

Summary: This study analyzed the effects of different treatment options in non-viral hepatocellular carcinoma patients. The results showed that lenvatinib treatment had better survival benefits compared to atezolizumab plus bevacizumab, particularly in patients with NAFLD/NASH-related HCC.

ESMO OPEN (2022)

Add to Collection

Article Oncology

Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma

Ahmed O. Kaseb et al.

Summary: This study demonstrates that baseline and dynamic changes in IGF-CTP and IGF-1 scores are independent prognostic factors for patients with unresectable HCC treated with specific therapies, providing potential improved patient stratification in future clinical trials.

JOURNAL OF HEPATOCELLULAR CARCINOMA (2022)

Add to Collection

Review Gastroenterology & Hepatology

Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma

Joseph C. Ahn et al.

Summary: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related morbidity and mortality worldwide, and current tests like alpha-fetoprotein have limited accuracy. Liver biopsy, while informative, is not routinely used due to invasiveness, leading to a need for new biomarkers. Liquid biopsy, specifically detection of circulating tumor cells (CTCs), offers potential for early detection and personalized treatment management in HCC patients. Quantitative analysis of CTCs can predict disease prognosis and treatment response, highlighting the importance of developing CTC detection platforms for clinical use.

HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma

Naga P. Chalasani et al.

Summary: A novel blood-based biomarker panel was developed for early-stage HCC detection, demonstrating high sensitivity. The panel outperformed other blood-based biomarkers, showing potential for clinically benefiting at-risk patients through liquid biopsy detection of early-stage HCC.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma

Johann von Felden et al.

Summary: This study reveals the mutational landscape of advanced HCC and identifies predictive biomarkers for response to systemic therapies. Mutations in the PI3K/MTOR pathway are associated with shorter PFS after tyrosine kinase inhibitor treatment, while WNT pathway mutations are not predictive of response after CPI therapy.

ONCOGENE (2021)

Add to Collection

Article Gastroenterology & Hepatology

BALAD and BALAD-2 predict survival of hepatocellular carcinoma patients: a North American cohort study

Nicha Wongjarupong et al.

Summary: The BALAD score and BALAD-2 class can effectively predict mortality risk in HCC patients in North America, with patients with cirrhosis having a significant impact on the prediction outcome. By incorporating a multivariate model, the accuracy of survival rate prediction for patients can be further improved.

HPB (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Gastroenterology & Hepatology

International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma

Amit G. Singal et al.

GASTROENTEROLOGY (2021)

Add to Collection

Review Oncology

MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review

Asahiro Morishita et al.

Summary: Hepatocellular carcinoma (HCC) is a common and deadly cancer, with a poor prognosis in late stages. Understanding the role of microRNAs (miRNAs) in HCC pathogenesis may lead to improved outcomes. MiRNAs have potential as valuable biomarkers and therapeutic targets in HCC diagnosis and treatment.

CANCERS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study

Jorn Lewin et al.

Summary: Hepatocellular carcinoma (HCC) is the leading cause of death in cirrhotic patients due to failed early detection. Methylation biomarkers in liquid biopsies provide a new alternative for HCC surveillance. Combination of DNA methylation markers with other biological markers, such as AFP, can improve overall clinical performance of surveillance.

BMC GASTROENTEROLOGY (2021)

Add to Collection

Article Oncology

Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma

Lorenza Rimassa et al.

Summary: Cabozantinib showed improved overall survival and progression-free survival versus placebo in previously treated advanced hepatocellular carcinoma patients, with various biomarkers favoring low and high baseline concentrations. Some biomarkers may serve as favorable prognostic factors, but none were predictive of treatment benefit. Cabozantinib-induced pharmacodynamic changes in biomarkers were observed, but not associated with patient survival.

LIVER CANCER (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Exosomal microRNAs as Biomarkers and Therapeutic Targets for Hepatocellular Carcinoma

Andrei Sorop et al.

Summary: Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and is often detected late due to its high clinical and biological heterogeneity. Small nanoparticles with an endosomal origin are valuable biomarkers or carriers for novel treatments in HCC.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Multidisciplinary Sciences

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister et al.

Summary: The study investigated the impact of NASH on immunotherapy response in HCC patients and found that NASH-HCC may be less responsive to immunotherapy. Aberrant T cell activation caused by NASH-related tissue damage led to impaired immune surveillance in HCC patients.

NATURE (2021)

Add to Collection

Review Oncology

Serum Biomarkers for the Prediction of Hepatocellular Carcinoma

Jose D. Debes et al.

Summary: Hepatocellular carcinoma (HCC) is a major cause of cancer death worldwide. Late diagnosis and limited treatment options contribute to the low survival rate of patients with HCC. Currently, combining ultrasound with the biomarker AFP is a commonly used screening method, but its clinical utility and operator-dependence are controversial.

CANCERS (2021)

Add to Collection

Article Oncology

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study

Richard S. Finn et al.

Summary: In the REFLECT study, lenvatinib showed noninferiority to sorafenib in terms of overall survival in unresectable hepatocellular carcinoma. Serum and tissue biomarker analysis revealed that higher baseline levels of VEGF, FGF21, and ANG2 were associated with shorter overall survival, and higher baseline FGF21 may predict longer overall survival with lenvatinib compared to sorafenib.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study

Zhenggang Ren et al.

Summary: The study aimed to assess the efficacy of sintilimab plus IBI305 versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma in China, showing significant overall survival and progression-free survival benefits with acceptable safety profiles.

LANCET ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

Thomas Powles et al.

Summary: The study found that using ctDNA testing to identify high-risk patients for relapse after surgery may improve treatment outcomes, with atezolizumab showing potential benefits in this patient population.

NATURE (2021)

Add to Collection

Review Oncology

Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?

Alice Boileve et al.

Summary: In the field of oncology, targeted and immune therapies have ushered in a new era over the last decade. While targeted agents are approved for hepatocellular carcinoma (HCC), immunotherapy is validated in combination with bevacizumab. Conversely, biliary tract cancer (BTC) is still investigational for immune therapies, with targeted therapies being crucial due to its complex molecular landscape. The review highlights the main prognostic and theragnostic biomarkers in HCC and BTC, as well as recommendations for clinical practice.

CANCERS (2021)

Add to Collection

Review Gastroenterology & Hepatology

Using cell-free DNA for HCC surveillance and prognosis

Nguyen H. Tran et al.

Summary: Hepatocellular carcinoma (HCC) is the most common primary liver cancer, and liquid biopsy has emerged as a promising strategy for analyzing circulating tumor DNA with potential clinical applications.

JHEP REPORTS (2021)

Add to Collection

Article Multidisciplinary Sciences

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister et al.

Summary: The text discusses the impact of NASH on the development of HCC and the effect of immunotherapy, revealing the accumulation of exhausted and unconventionally activated CD8(+)PD1(+) T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, anti-PD1 treatment led to an increase in HCC, with CD8(+) T cells contributing to this increase.

NATURE (2021)

Add to Collection

Article Oncology

Perioperative circulating tumor DNA analysis to predict patient prognosis in liver cancer.

Ledu Zhou et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Longitudinal and personalized detection of circulating tumor DNA (ctDNA) for monitoring efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC).

Chih-Hung Hsu et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Review Cell Biology

Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment

Federico Pinero et al.

CELLS (2020)

Add to Collection

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

The diagnostic value of the combination of Golgi protein 73, glypican-3 and alpha-fetoprotein in hepatocellular carcinoma: a diagnostic meta-analysis

Shoujie Zhao et al.

ANNALS OF TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Oncology

Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma

Jian Wang et al.

ANNALS OF TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Gastroenterology & Hepatology

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

Bruno Sangro et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Review Medicine, General & Internal

Clinical value of circulating tumor cells for the diagnosis and prognosis of hepatocellular carcinoma (HCC) A systematic review and meta-analysis

Kai Cui et al.

MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

MLH1 single-nucleotide variant in circulating tumor DNA predicts overall survival of patients with hepatocellular carcinoma

Soon Sun Kim et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Article Oncology

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial

Thomas Yau et al.

JAMA ONCOLOGY (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma

Xiaolin Wu et al.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2020)

Add to Collection

Review Medicine, Research & Experimental

Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis

Jicheng Wu et al.

THERANOSTICS (2020)

Add to Collection

Article Gastroenterology & Hepatology

Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma

Jonggi Choi et al.

HEPATOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma

Michael Teufel et al.

GASTROENTEROLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma

Xu Ye et al.

HEPATOLOGY (2019)

Add to Collection

Review Genetics & Heredity

Detection of Solid Tumor Molecular Residual Disease(MRD) Using Circulating Tumor DNA (ctDNA)

Re-I Chin et al.

MOLECULAR DIAGNOSIS & THERAPY (2019)

Add to Collection

Article Oncology

Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials

Robert Montal et al.

BRITISH JOURNAL OF CANCER (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA

Qianwei Ye et al.

MOLECULAR CANCER (2019)

Add to Collection

Article Gastroenterology & Hepatology

Performance of Serum Glypican 3 in Diagnosis of Hepatocellular Carcinoma: A meta-analysis

Dahai Xu et al.

ANNALS OF HEPATOLOGY (2019)

Add to Collection

Article Oncology

GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score

Ju Dong Yang et al.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2019)

Add to Collection

Article Medicine, Research & Experimental

Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute's Early Detection Research Network

Kelly A. Borges et al.

CONTEMPORARY CLINICAL TRIALS (2019)

Add to Collection

Article Gastroenterology & Hepatology

Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma

Jian-Hong Fang et al.

HEPATOLOGY (2019)

Add to Collection

Article Oncology

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study

Ziding Feng et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)

Add to Collection

Meeting Abstract Oncology

Circulating cell-free DNA methylation assay: Towards early detection of multiple cancer types

Dhruvajyoti Roy et al.

CANCER RESEARCH (2019)

Add to Collection

Article Gastroenterology & Hepatology

Correlation Between Postoperative Early Recurrence of Hepatocellular Carcinoma and Mesenchymal Circulating Tumor Cells in Peripheral Blood

Zhong Wang et al.

JOURNAL OF GASTROINTESTINAL SURGERY (2018)

Add to Collection

Article Oncology

Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma

Lu-Nan Qi et al.

CANCER RESEARCH (2018)

Add to Collection

Article Gastroenterology & Hepatology

Circulating Tumor Cell Phenotype Indicates Poor Survival and Recurrence After Surgery for Hepatocellular Carcinoma

Huohui Ou et al.

DIGESTIVE DISEASES AND SCIENCES (2018)

Add to Collection

Article Gastroenterology & Hepatology

Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis

Kristina Tzartzeva et al.

GASTROENTEROLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Jorge A. Marrero et al.

HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Peter R. Galle et al.

JOURNAL OF HEPATOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

Add to Collection

Article Oncology

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma

Colin M. Court et al.

LIVER TRANSPLANTATION (2018)

Add to Collection

Article Medicine, General & Internal

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

G. K. Abou-Alfa et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Review Biochemistry & Molecular Biology

The significance of intertumor and intratumor heterogeneity in liver cancer

Jinping Liu et al.

EXPERIMENTAL AND MOLECULAR MEDICINE (2018)

Add to Collection

Article Gastroenterology & Hepatology

Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Masao Omata et al.

HEPATOLOGY INTERNATIONAL (2017)

Add to Collection

Article Gastroenterology & Hepatology

Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey

Hienori Toyoda et al.

JOURNAL OF GASTROENTEROLOGY (2017)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

A randomized controlled trial of US vs US plus biomarkers for the diagnosis of hepatocellular carcinoma: an interim report

M. Sherman et al.

JOURNAL OF HEPATOLOGY (2017)

Add to Collection

Article Gastroenterology & Hepatology

Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies

Jordi Bruix et al.

JOURNAL OF HEPATOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix et al.

LANCET (2017)

Add to Collection

Article Medicine, General & Internal

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry et al.

LANCET (2017)

Add to Collection

Review Medicine, General & Internal

The diagnostic value of assays for circulating tumor cells in hepatocellular carcinoma A meta-analysis

Chi Sun et al.

MEDICINE (2017)

Add to Collection

Article Chemistry, Physical

Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma

Rui-hua Xu et al.

NATURE MATERIALS (2017)

Add to Collection

Review Immunology

Human Tumor-infiltrating Myeloid Cells: Phenotypic and Functional Diversity

Louise A. Elliott et al.

FRONTIERS IN IMMUNOLOGY (2017)

Add to Collection

Article Oncology

Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data

Rentao Yu et al.

BMC CANCER (2017)

Add to Collection

Article Oncology

Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection

Yan Zhou et al.

BMC CANCER (2016)

Add to Collection

Article Gastroenterology & Hepatology

Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients

Sarah Berhane et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)

Add to Collection

Article Cell Biology

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

Jeanne Tie et al.

SCIENCE TRANSLATIONAL MEDICINE (2016)

Add to Collection

Article Oncology

Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection

Abdel-Rahman Nabawy Zekri et al.

TUMOR BIOLOGY (2016)

Add to Collection

Review Gastroenterology & Hepatology

Challenges of advanced hepatocellular carcinoma

Stefano Colagrande et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2016)

Add to Collection

Review Gastroenterology & Hepatology

Hepatocellular carcinoma: Review of disease and tumor biomarkers

Jin Un Kim et al.

WORLD JOURNAL OF HEPATOLOGY (2016)

Add to Collection

Article Oncology

Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls

Robin K. Kelley et al.

BMC CANCER (2015)

Add to Collection

Article Gastroenterology & Hepatology

Elevated Alpha-Fetoprotein Differential Diagnosis - Hepatocellular Carcinoma and Other Disorders

Robert J. Wong et al.

CLINICS IN LIVER DISEASE (2015)

Add to Collection

Article Oncology

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Oncology

A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study

Xue-Jia Lin et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Gastroenterology & Hepatology

Biomarkers for the early diagnosis of hepatocellular carcinoma

Nobuhiro Tsuchiya et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2015)

Add to Collection

Article Oncology

Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance

Ke-Qing Shi et al.

ONCOTARGET (2015)

Add to Collection

Review Oncology

Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma

Reham Abdel-Wahab et al.

JOURNAL OF HEPATOCELLULAR CARCINOMA (2015)

Add to Collection

Article Oncology

Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model

R. Fox et al.

BRITISH JOURNAL OF CANCER (2014)

Add to Collection

Article Oncology

The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers

Philip J. Johnson et al.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)

Add to Collection

Article Oncology

Clinical Significance of EpCAM mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR-Based Platform

Wei Guo et al.

CLINICAL CANCER RESEARCH (2014)

Add to Collection

Article Oncology

Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

Maxime Ronot et al.

ONCOLOGIST (2014)

Add to Collection

Article Surgery

Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma

Junichi Shindoh et al.

TRANSPLANT INTERNATIONAL (2014)

Add to Collection

Article Medicine, General & Internal

Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis

Amit G. Singal et al.

PLOS MEDICINE (2014)

Add to Collection

Article Oncology

Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma

Kornelius Schulze et al.

INTERNATIONAL JOURNAL OF CANCER (2013)

Add to Collection

Article Multidisciplinary Sciences

Strength of PD-1 signaling differentially affects T-cell effector functions

Fang Wei et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)

Add to Collection

Article Medicine, General & Internal

Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

Douglas G. Altman et al.

BMC MEDICINE (2012)

Add to Collection

Article Oncology

Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

Josep M. Llovet et al.

CLINICAL CANCER RESEARCH (2012)

Add to Collection

Article Gastroenterology & Hepatology

Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria

Christophe Duvoux et al.

GASTROENTEROLOGY (2012)

Add to Collection

Article Gastroenterology & Hepatology

Prediction of recurrence of hepatocellular carcinoma after curative hepatectomy using preoperative Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein

Yu Saito et al.

HEPATOLOGY RESEARCH (2012)

Add to Collection

Article Gastroenterology & Hepatology

Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses

Jean-Luc Raoul et al.

JOURNAL OF HEPATOLOGY (2012)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

Jordi Bruix et al.

JOURNAL OF HEPATOLOGY (2012)

Add to Collection

Article Oncology

Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study

Qiujin Shen et al.

LANCET ONCOLOGY (2012)

Add to Collection

Article Surgery

Triple Positive Tumor Markers for Hepatocellular Carcinoma Are Useful Predictors of Poor Survival

Shigehisa Kiriyama et al.

ANNALS OF SURGERY (2011)

Add to Collection

Article Gastroenterology & Hepatology

Des-γ-Carboxy Prothrombin and α-Fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma

Anna S. Lok et al.

GASTROENTEROLOGY (2010)

Add to Collection

Article Gastroenterology & Hepatology

Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis

A. Singal et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)

Add to Collection

Article Surgery

Significance of Des-Gamma-Carboxy Prothrombin in Selection Criteria for Living Donor Liver Transplantation for Hepatocellular Carcinoma

M. Fujiki et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2009)

Add to Collection

Article Oncology

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann-Lii Cheng et al.

LANCET ONCOLOGY (2009)

Add to Collection

Article Immunology

Impact of Des-Gamma-Carboxy Prothrombin and Tumor Size on the Recurrence of Hepatocellular Carcinoma After Living Donor Liver Transplantation

Akinobu Taketomi et al.

TRANSPLANTATION (2009)

Add to Collection

Article Gastroenterology & Hepatology

Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma

Wei-Feng Shen et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2009)

Add to Collection

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

Article Gastroenterology & Hepatology

Clinical evaluation of lens culinaris agglutinin-reactive α-fetoprotein and des-γ-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States

Brian I. Carr et al.

DIGESTIVE DISEASES AND SCIENCES (2007)

Add to Collection

Article Gastroenterology & Hepatology

Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers

Hidenori Toyoda et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)

Add to Collection

Article Gastroenterology & Hepatology

Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: A systematic review

A Colli et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)

Add to Collection

Article Gastroenterology & Hepatology

Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial

AM Di Bisceglie et al.

JOURNAL OF HEPATOLOGY (2005)

Add to Collection

Article Oncology

Randomized controlled trial of screening for hepatocellular carcinoma

BH Zhang et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2004)

Add to Collection

Review Medical Laboratory Technology

Alpha-fetoprotein in the early neonatal period - a large study and review of the literature

D Bader et al.

CLINICA CHIMICA ACTA (2004)

Add to Collection

Article Pathology

Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma

B Yang et al.

AMERICAN JOURNAL OF PATHOLOGY (2003)

Add to Collection

Article Gastroenterology & Hepatology

Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients

JA Marrero et al.

HEPATOLOGY (2003)

Add to Collection

Article Public, Environmental & Occupational Health

Screening for liver cancer: results of a randomised controlled trial in Qidong, China

JG Chen et al.

JOURNAL OF MEDICAL SCREENING (2003)

Add to Collection

Article Oncology

AFP-Producing gastric carcinoma: Multivariate analysis of prognostic factors in 270 patients

Y Adachi et al.

ONCOLOGY (2003)

Add to Collection

Review Medicine, Research & Experimental

Alpha-fetoprotein structure and function: Relevance to isoforms, epitopes, and conformational variants

GJ Mizejewski

EXPERIMENTAL BIOLOGY AND MEDICINE (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.